Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea
· Delayed Price · Currency is KRW 83,300
-100 (-0.12%)
Last updated: Jun 27, 2025
KRX:185750 Revenue
Chong Kun Dang Pharmaceutical had revenue of 400.96B KRW in the quarter ending March 31, 2025, with 10.91% growth. This brings the company's revenue in the last twelve months to 1.63T, down -2.39% year-over-year. In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T, down -4.97%.
Revenue (ttm)
1,625.88B
Revenue Growth
-2.39%
P/S Ratio
0.67
Revenue / Employee
714.36M
Employees
2,276
Market Cap
1,085.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,586.43B | -82.97B | -4.97% |
| Dec 31, 2023 | 1,669.40B | 181.06B | 12.17% |
| Dec 31, 2022 | 1,488.34B | 144.79B | 10.78% |
| Dec 31, 2021 | 1,343.56B | 40.55B | 3.11% |
| Dec 31, 2020 | 1,303.01B | 223.67B | 20.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |
| Peptron | 4.30B |